Key result
HSV-2 co-infection in HIV-positive pregnant women is not linked to increased mother-to-child transmission.
Why the study?
HSV-2 co-infection may increase HIV mother-to-child transmission risk among HIV-positive women in Ukraine, a setting with high STI prevalence.
Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?
Cohort (n=1,513)
Yes
Does HSV-2 co-infection increase HIV mother-to-child transmission in HIV-positive women?
HSV-2 co-infection does not significantly increase the risk of HIV mother-to-child transmission among HIV-positive women receiving high rates of antenatal antiretroviral therapy.
Answers are grounded in this paper and cite their sources.
HSV-2 co-infection should not yet influence MTCT risk counseling in HIV pregnancies; leaves open confirmation in larger prospective cohorts.
BACKGROUND: Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk. We explored factors associated with HSV-2 seropositivity among HIV-positive women in Ukraine, and its impact on HIV MTCT. METHODS: Data on 1513 HIV-positive women enrolled in the Ukraine European Collaborative Study from 2007 to 2012 were analysed. Poisson and logistic regression models respectively were fit to investigate factors associated with HSV-2 seropositivity and HIV MTCT. RESULTS: Median maternal age was 27 years (IQR 24-31), 53% (796/1513) had been diagnosed with HIV during their most recent pregnancy and 20% had a history of injecting drugs. Median antenatal CD4 count was 430 cells/mm(3) (IQR 290-580). Ninety-six percent had received antiretroviral therapy antenatally. HSV-2 seroprevalence was 68% (1026/1513). In adjusted analyses, factors associated with HSV-2 antibodies were history of pregnancy termination (APR 1.30 (95% CI 1.18-1.43) for ≥ 2 vs. 0), having an HIV-positive partner (APR 1.15 (95% CI 1.05-1.26) vs partner's HIV status unknown) and HCV seropositivity (APR 1.23 (95 % CI 1.13-1.35)). The overall HIV MTCT rate was 2.80% (95% CI 1.98-3.84); no increased HIV MTCT risk was detected among HSV-2 seropositive women after adjusting for known risk factors (AOR 1.43 (95% CI 0.54-3.77). CONCLUSION: No increased risk of HIV MTCT was detected among the 68% of HIV-positive women with antibodies to HSV-2, in this population with an overall HIV MTCT rate of 2.8%. Markers of ongoing sexual risk among HIV-positive HSV-2 seronegative women indicate the importance of interventions to prevent primary HSV-2 infection during pregnancy in this high-risk group.
No takes yet. Share an insight, caveat, or question.
Aebi‐Popp et al. (2016) conducted a cohort in HIV in pregnancy (n=1,513). HSV-2 co-infection vs. HSV-2 seronegative was evaluated on HIV mother-to-child transmission (MTCT) (AOR 1.43, 95% CI 0.54-3.77, p=0.474). HSV-2 co-infection in HIV-positive pregnant women was not associated with an increased risk of HIV mother-to-child transmission.
Synapse has enriched 10 related papers. Consider them for comparative context: